HEADER TRANSFERASE 08-APR-10 2XBA TITLE STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA- TITLE 2 E429 COMPND MOL_ID: 1; COMPND 2 MOLECULE: ALK TYROSINE KINASE RECEPTOR; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: KINASE DOMAIN, RESIDUES 1094-1407; COMPND 5 SYNONYM: ANAPLASTIC LYMPHOMA KINASE, CD246; COMPND 6 EC: 2.7.10.1; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: SF9; SOURCE 8 EXPRESSION_SYSTEM_VECTOR: PVL1393; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PVL-GST-ALK-KD KEYWDS ATP-BINDING, RECEPTOR, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR R.T.BOSSI,M.B.SACCARDO,E.ARDINI,M.MENICHINCHERI,L.RUSCONI,P.MAGNAGHI, AUTHOR 2 P.ORSINI,G.FOGLIATTO,J.A.BERTRAND REVDAT 3 01-MAY-24 2XBA 1 REMARK REVDAT 2 25-AUG-10 2XBA 1 JRNL REVDAT 1 28-JUL-10 2XBA 0 JRNL AUTH R.T.BOSSI,M.B.SACCARDO,E.ARDINI,M.MENICHINCHERI,L.RUSCONI, JRNL AUTH 2 P.MAGNAGHI,P.ORSINI,N.AVANZI,A.L.BORGIA,M.NESI,T.BANDIERA, JRNL AUTH 3 G.FOGLIATTO,J.A.BERTRAND JRNL TITL CRYSTAL STRUCTURES OF ANAPLASTIC LYMPHOMA KINASE IN COMPLEX JRNL TITL 2 WITH ATP COMPETITIVE INHIBITORS. JRNL REF BIOCHEMISTRY V. 49 6813 2010 JRNL REFN ISSN 0006-2960 JRNL PMID 20695522 JRNL DOI 10.1021/BI1005514 REMARK 2 REMARK 2 RESOLUTION. 1.95 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2005 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.95 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 38.73 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1404564.520 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.4 REMARK 3 NUMBER OF REFLECTIONS : 23394 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.195 REMARK 3 R VALUE (WORKING SET) : 0.193 REMARK 3 FREE R VALUE : 0.229 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1180 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.007 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.95 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.07 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.70 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 3668 REMARK 3 BIN R VALUE (WORKING SET) : 0.2330 REMARK 3 BIN FREE R VALUE : 0.2740 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.90 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 187 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.020 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2245 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 34 REMARK 3 SOLVENT ATOMS : 136 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 18.20 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 26.60 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.16000 REMARK 3 B22 (A**2) : 1.43000 REMARK 3 B33 (A**2) : -1.27000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.21 REMARK 3 ESD FROM SIGMAA (A) : 0.15 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.26 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.17 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.012 REMARK 3 BOND ANGLES (DEGREES) : 1.200 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 19.80 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.930 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.38 REMARK 3 BSOL : 48.45 REMARK 3 REMARK 3 NCS MODEL : NONE REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.P REMARK 3 PARAMETER FILE 2 : WATER_REP.PAR REMARK 3 PARAMETER FILE 3 : 571.PAR REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : 571.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2XBA COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 08-APR-10. REMARK 100 THE DEPOSITION ID IS D_1290043586. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 27-NOV-06 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID23-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.979250 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 23448 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.950 REMARK 200 RESOLUTION RANGE LOW (A) : 57.780 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 200 DATA REDUNDANCY : 4.700 REMARK 200 R MERGE (I) : 0.09000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 16.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.95 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.06 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.8 REMARK 200 DATA REDUNDANCY IN SHELL : 4.60 REMARK 200 R MERGE FOR SHELL (I) : 0.45000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.900 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: INTERNAL STRUCTURE OF IGF-1R REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 44.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.20 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20% PEG3350, 0.15 M DL-MALIC ACID REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.94200 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 52.77050 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 28.50650 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 52.77050 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.94200 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 28.50650 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 1093 REMARK 465 PRO A 1094 REMARK 465 GLY A 1123 REMARK 465 HIS A 1124 REMARK 465 GLY A 1125 REMARK 465 ALA A 1126 REMARK 465 PHE A 1127 REMARK 465 GLY A 1128 REMARK 465 GLU A 1129 REMARK 465 GLY A 1137 REMARK 465 MET A 1138 REMARK 465 PRO A 1139 REMARK 465 ASN A 1140 REMARK 465 ASP A 1141 REMARK 465 PRO A 1142 REMARK 465 SER A 1143 REMARK 465 ARG A 1279 REMARK 465 ALA A 1280 REMARK 465 SER A 1281 REMARK 465 TYR A 1282 REMARK 465 TYR A 1283 REMARK 465 ARG A 1284 REMARK 465 LYS A 1285 REMARK 465 GLY A 1286 REMARK 465 GLY A 1287 REMARK 465 CYS A 1288 REMARK 465 PRO A 1403 REMARK 465 LEU A 1404 REMARK 465 VAL A 1405 REMARK 465 GLU A 1406 REMARK 465 GLU A 1407 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLY A1402 CA C O REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A1248 -4.66 77.63 REMARK 500 ASP A1249 51.98 -151.81 REMARK 500 SER A1332 -9.41 91.30 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 571 A 1501 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2XB7 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- REMARK 900 TAE684 DBREF 2XBA A 1094 1407 UNP Q9UM73 ALK_HUMAN 1094 1407 SEQADV 2XBA GLY A 1093 UNP Q9UM73 EXPRESSION TAG SEQRES 1 A 315 GLY PRO ASN TYR CYS PHE ALA GLY LYS THR SER SER ILE SEQRES 2 A 315 SER ASP LEU LYS GLU VAL PRO ARG LYS ASN ILE THR LEU SEQRES 3 A 315 ILE ARG GLY LEU GLY HIS GLY ALA PHE GLY GLU VAL TYR SEQRES 4 A 315 GLU GLY GLN VAL SER GLY MET PRO ASN ASP PRO SER PRO SEQRES 5 A 315 LEU GLN VAL ALA VAL LYS THR LEU PRO GLU VAL CYS SER SEQRES 6 A 315 GLU GLN ASP GLU LEU ASP PHE LEU MET GLU ALA LEU ILE SEQRES 7 A 315 ILE SER LYS PHE ASN HIS GLN ASN ILE VAL ARG CYS ILE SEQRES 8 A 315 GLY VAL SER LEU GLN SER LEU PRO ARG PHE ILE LEU LEU SEQRES 9 A 315 GLU LEU MET ALA GLY GLY ASP LEU LYS SER PHE LEU ARG SEQRES 10 A 315 GLU THR ARG PRO ARG PRO SER GLN PRO SER SER LEU ALA SEQRES 11 A 315 MET LEU ASP LEU LEU HIS VAL ALA ARG ASP ILE ALA CYS SEQRES 12 A 315 GLY CYS GLN TYR LEU GLU GLU ASN HIS PHE ILE HIS ARG SEQRES 13 A 315 ASP ILE ALA ALA ARG ASN CYS LEU LEU THR CYS PRO GLY SEQRES 14 A 315 PRO GLY ARG VAL ALA LYS ILE GLY ASP PHE GLY MET ALA SEQRES 15 A 315 ARG ASP ILE TYR ARG ALA SER TYR TYR ARG LYS GLY GLY SEQRES 16 A 315 CYS ALA MET LEU PRO VAL LYS TRP MET PRO PRO GLU ALA SEQRES 17 A 315 PHE MET GLU GLY ILE PHE THR SER LYS THR ASP THR TRP SEQRES 18 A 315 SER PHE GLY VAL LEU LEU TRP GLU ILE PHE SER LEU GLY SEQRES 19 A 315 TYR MET PRO TYR PRO SER LYS SER ASN GLN GLU VAL LEU SEQRES 20 A 315 GLU PHE VAL THR SER GLY GLY ARG MET ASP PRO PRO LYS SEQRES 21 A 315 ASN CYS PRO GLY PRO VAL TYR ARG ILE MET THR GLN CYS SEQRES 22 A 315 TRP GLN HIS GLN PRO GLU ASP ARG PRO ASN PHE ALA ILE SEQRES 23 A 315 ILE LEU GLU ARG ILE GLU TYR CYS THR GLN ASP PRO ASP SEQRES 24 A 315 VAL ILE ASN THR ALA LEU PRO ILE GLU TYR GLY PRO LEU SEQRES 25 A 315 VAL GLU GLU HET 571 A1501 34 HETNAM 571 5-[(2R)-2-HYDROXY-2-PHENYLACETYL]-3-({[4-(4- HETNAM 2 571 METHYLPIPERAZIN-1-YL)PHENYL]CARBONYL}AMINO)-1,6- HETNAM 3 571 DIHYDROPYRROLO[3,4-C]PYRAZOL-5-IUM FORMUL 2 571 C25 H27 N6 O3 1+ FORMUL 3 HOH *136(H2 O) HELIX 1 1 SER A 1104 LEU A 1108 5 5 HELIX 2 2 PRO A 1112 LYS A 1114 5 3 HELIX 3 3 SER A 1157 PHE A 1174 1 18 HELIX 4 4 LEU A 1204 ARG A 1212 1 9 HELIX 5 5 ALA A 1222 ASN A 1243 1 22 HELIX 6 6 ALA A 1251 ARG A 1253 5 3 HELIX 7 7 PHE A 1271 TYR A 1278 1 8 HELIX 8 8 PRO A 1292 MET A 1296 5 5 HELIX 9 9 PRO A 1297 GLU A 1303 1 7 HELIX 10 10 THR A 1307 SER A 1324 1 18 HELIX 11 11 SER A 1334 SER A 1344 1 11 HELIX 12 12 PRO A 1355 TRP A 1366 1 12 HELIX 13 13 GLN A 1369 ARG A 1373 5 5 HELIX 14 14 ASN A 1375 ASP A 1389 1 15 HELIX 15 15 ASP A 1389 ASN A 1394 1 6 SHEET 1 AA 2 TYR A1096 PHE A1098 0 SHEET 2 AA 2 LYS A1101 SER A1103 -1 O LYS A1101 N PHE A1098 SHEET 1 AB 5 ILE A1116 GLY A1121 0 SHEET 2 AB 5 TYR A1131 VAL A1135 -1 O GLU A1132 N ILE A1119 SHEET 3 AB 5 LEU A1145 THR A1151 -1 O LEU A1145 N VAL A1135 SHEET 4 AB 5 PHE A1193 GLU A1197 -1 O ILE A1194 N LYS A1150 SHEET 5 AB 5 CYS A1182 SER A1186 -1 N ILE A1183 O LEU A1195 SHEET 1 AC 3 GLY A1202 ASP A1203 0 SHEET 2 AC 3 CYS A1255 LEU A1257 -1 N LEU A1257 O GLY A1202 SHEET 3 AC 3 ALA A1266 ILE A1268 -1 O LYS A1267 N LEU A1256 CISPEP 1 LEU A 1190 PRO A 1191 0 -3.83 SITE 1 AC1 14 ALA A1148 LYS A1150 GLU A1197 LEU A1198 SITE 2 AC1 14 MET A1199 ALA A1200 GLY A1202 GLU A1210 SITE 3 AC1 14 ARG A1253 ASN A1254 LEU A1256 HOH A2075 SITE 4 AC1 14 HOH A2135 HOH A2136 CRYST1 51.884 57.013 105.541 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019274 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017540 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009475 0.00000